Literature DB >> 18447717

Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation.

Peter J Dickinson1, Richard A LeCouteur, Robert J Higgins, John R Bringas, Byron Roberts, Richard F Larson, Yoji Yamashita, Michal Krauze, Charles O Noble, Daryl Drummond, Dmitri B Kirpotin, John W Park, Mitchel S Berger, Krystof S Bankiewicz.   

Abstract

OBJECT: Many factors relating to the safety and efficacy of convection-enhanced delivery (CED) into intracranial tumors are poorly understood. To investigate these factors further and establish a more clinically relevant large animal model, with the potential to investigate CED in large, spontaneous tumors, the authors developed a magnetic resonance (MR) imaging-compatible system for CED of liposomal nanoparticles into the canine brain, incorporating real-time MR imaging. Additionally any possible toxicity of liposomes containing Gd and the chemotherapeutic agent irinotecan (CPT-11) was assessed following direct intraparenchymal delivery.
METHODS: Four healthy laboratory dogs were infused with liposomes containing Gd, rhodamine, or CPT-11. Convection-enhanced delivery was monitored in real time by sequential MR imaging, and the volumes of distribution were calculated from MR images and histological sections. Assessment of any toxicity was based on clinical and histopathological evaluation. Convection-enhanced delivery resulted in robust volumes of distribution in both gray and white matter, and real-time MR imaging allowed accurate calculation of volumes and pathways of distribution.
RESULTS: Infusion variability was greatest in the gray matter, and was associated with leakage into ventricular or subarachnoid spaces. Complications were minimal and included mild transient proprioceptive deficits, focal hemorrhage in 1 dog, and focal, mild perivascular, nonsuppurative encephalitis in 1 dog.
CONCLUSIONS: Convection-enhanced delivery of liposomal Gd/CPT-11 is associated with minimal adverse effects in a large animal model, and further assessment for use in clinical patients is warranted. Future studies investigating real-time monitored CED in spontaneous gliomas in canines are feasible and will provide a unique, clinically relevant large animal translational model for testing this and other therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18447717     DOI: 10.3171/JNS/2008/108/5/0989

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  41 in total

1.  Analysis of a simulation algorithm for direct brain drug delivery.

Authors:  Kathryn Hammond Rosenbluth; Jan Felix Eschermann; Gabriele Mittermeyer; Rowena Thomson; Stephan Mittermeyer; Krystof S Bankiewicz
Journal:  Neuroimage       Date:  2011-09-14       Impact factor: 6.556

2.  Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

Authors:  Laura P Serwer; Charles O Noble; Karine Michaud; Daryl C Drummond; Dmitri B Kirpotin; Tomoko Ozawa; Michael D Prados; John W Park; C David James
Journal:  Neuro Oncol       Date:  2011-09-27       Impact factor: 12.300

3.  EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.

Authors:  Costas G Hadjipanayis; Revaz Machaidze; Milota Kaluzova; Liya Wang; Albert J Schuette; Hongwei Chen; Xinying Wu; Hui Mao
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

Review 4.  Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.

Authors:  Mayur M Patel; Bhoomika M Patel
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 5.  Convection-Enhanced Delivery.

Authors:  A M Mehta; A M Sonabend; J N Bruce
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 6.  Convection-enhanced drug delivery for glioblastoma: a review.

Authors:  Randy S D'Amico; Manish K Aghi; Michael A Vogelbaum; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

7.  Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model.

Authors:  Randy S D'Amico; Justin A Neira; Jonathan Yun; Nikita G Alexiades; Matei Banu; Zachary K Englander; Benjamin C Kennedy; Timothy H Ung; Robert J Rothrock; Alexander Romanov; Xiaotao Guo; Binsheng Zhao; Adam M Sonabend; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurosurg       Date:  2019-08-02       Impact factor: 5.115

Review 8.  Convection-enhanced delivery for the treatment of brain tumors.

Authors:  Waldemar Debinski; Stephen B Tatter
Journal:  Expert Rev Neurother       Date:  2009-10       Impact factor: 4.618

Review 9.  Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.

Authors:  Leon Chen; Yuqing Zhang; Jingxuan Yang; John P Hagan; Min Li
Journal:  Biochim Biophys Acta       Date:  2013-04-22

10.  Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.

Authors:  Amy Y Grahn; Krystof S Bankiewicz; Millicent Dugich-Djordjevic; John R Bringas; Piotr Hadaczek; Greg A Johnson; Simon Eastman; Matthias Luz
Journal:  J Neurooncol       Date:  2009-05-24       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.